The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Combination regimens to address resistance to menin inhibitors in AML
Jacqueline Garcia, MD, Dana Farber Cancer Institute, Boston, MA, comments on the importance of strategic combination regimens to address resistance and deepen response in patients with acute myeloid leukemia (AML) receiving menin inhibitors. Dr Garcia emphasizes the potential benefits of combining menin inhibitors with other novel therapies to prevent or address resistance. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
